A new gene therapy treats an inherited disorder by changing the body cells of adult patients. The therapy costs over £1 million per patient and is offered in only a few countries.
Which ethical question does this information most directly raise?
Who owns the genetic material used in the therapy?
Have the patients agreed to receive the therapy?
Will the change be passed on to the patients' children?
Can everyone who needs the therapy receive it?
100 exam-style questions on Edexcel GCSE Biology 4.3 Selective breeding and genetic modification, covering 4.3.1 Selective breeding and its impact, 4.3.2 Tissue culture, 4.3.3 Genetic engineering overview, 4.3.4 Main stages of genetic engineering, 4.3.5 Advantages and disadvantages of GM organisms, 4.3.6 Agricultural solutions for a growing population, and 4.3.7 Evaluating genetic engineering and breeding. Each one has a worked solution and a mark scheme showing where the marks go.